Immix Biopharma Inc (IMMX)

Immix Biopharma Inc (IMMX) is a Biotechnology company in the Healthcare sector listed on the NASDAQ.

As of Oct 23, 2026: market cap $803M; returns 1 day -2.4%, 1 week +2.1%, 1 year +137.6%.

Immix Biopharma Inc. is a clinical-stage biopharmaceutical company primarily focused on the discovery and development of novel cell therapies for hematologic malignancies and immune-dysregulated diseases. Its lead product candidate, NXC-201, is a sterically-optimized BCMA-targeted Chimeric Antigen Receptor T (CAR-T) cell therapy.

Groups IMMX belongs to

• Biotechnology
• Clinical Stage Biopharma
• Biopharmaceutical
• Clinical Stage
• Autologous Cell Therapy
• Hematologic Malignancies
• Oncology
• Rare Diseases
• Autoimmune Diseases
• Healthcare
• Life Sciences

IMMX financial model: income statement, cash flow and balance sheet